Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06494995 2025-06-04

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Phase 2 Recruiting

52 enrolled

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

Phase 2 Not yet recruiting

62 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

100 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

664 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Phase 2 Not yet recruiting

150 enrolled

Head & Neck

Nasopharyngeal Neoplasms, Recurrence

NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Recruiting

400 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

166 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

169 enrolled

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

264 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06331845 2024-03-26

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

39 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06259721 2024-03-07

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

22 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02524275 2023-09-08

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Terminated

14 enrolled 10 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Phase 2 Unknown

51 enrolled

Head & Neck

Hypopharyngeal Neoplasms

NCT05965154 2023-07-28

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

22 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02611960 2023-07-13

Keynote-122

Phase 3 Completed

233 enrolled 21 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Nasopharyngeal Neoplasms

NCT04072107 2023-06-18

EP-STAR

Phase 2 Unknown

110 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02940925 2023-04-12

TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma

Phase 3 Completed

241 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT00258310 2023-03-10

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

Phase 2 Completed

35 enrolled 7 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Phase 2 Unknown

84 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05717764 2023-02-08

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Phase 3 Not yet recruiting

500 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03775525 2022-12-23

GEN602

Phase 1 Unknown

127 enrolled

BreastDermatologicGastrointestinalHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Basal Cell, Colonic Neoplasms, Lymphoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT02460419 2022-10-28